Whitehawk Therapeutics Expands ADC Pipeline with Hangzhou DAC Option Agreement
Event summary
- Whitehawk Therapeutics secured an option agreement with Hangzhou DAC for access to CPT113 linker-payload technology for up to five new ADC programs.
- The agreement allows Whitehawk to select targets, source antibodies, and retain global rights for new ADC programs.
- Whitehawk anticipates submitting IND applications for multiple new programs within the next 12-24 months.
- Phase 1 trials for HWK-007 and HWK-016 are currently enrolling, with data expected in the first half of 2027.
The big picture
Whitehawk Therapeutics is leveraging the CPT113 linker-payload technology to expand its ADC pipeline, building on external validation from programs like Hangzhou DAC's DXC006 and Johnson & Johnson's JNJ-95437446. This strategic move positions Whitehawk to compete in the rapidly evolving ADC space, where stability and therapeutic index are critical differentiators. The company's ability to scale its pipeline and deliver on its clinical milestones will be key to its long-term success in oncology.
What we're watching
- Pipeline Execution
- Whether Whitehawk can successfully advance multiple new ADC programs toward the clinic within the next 12-24 months.
- Clinical Validation
- The pace at which Phase 1 data for HWK-007 and HWK-016 will validate the efficacy and safety of Whitehawk's ADC platform.
- Competitive Positioning
- How Whitehawk's proprietary CBCR bioconjugation process will differentiate its ADCs in a competitive oncology market.
Related topics